• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Maternal BNT162b2 (Pfizer-BioNTech) COVID-19 vaccination is not associated with adverse neonatal or early infant outcomes  

byMolly MunsellandAlex Gipsman, MD
February 22, 2022
in Infectious Disease, Obstetrics, Pediatrics, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In a large cohort study, infants whose mothers received the BNT162b2 vaccine during pregnancy were not significantly more likely to be born preterm.

2. There were no significant differences in infant mortality, congenital anomalies, or infant hospitalization based on maternal vaccination status.

Evidence Rating Level: 2 (Good)

Study Rundown: Pregnant patients were excluded from early trials of COVID-19 vaccinations, including Pfizer-BioNTech’s BNT162b2 mRNA vaccine. The vaccine is now recommended and routinely administered in pregnancy in part due to early studies suggesting a high degree of safety. However, this is the first large-scale study reporting neonatal outcomes for this vaccine. Nearly 17,000 Israeli infants with prenatal vaccine exposure were compared to about 7,600 infants unexposed to vaccine. Median follow-up was about 4.5 months, with a minimum of one month. There was no association between vaccine exposure and rates of preterm birth, low birth weight, or very low birth weight. There were also no significant between-group differences in rates of all-cause infant mortality, all-cause neonatal or post-neonatal hospitalizations, or phototherapy during the study period. Infants whose mothers were vaccinated during the first trimester were not significantly more likely to have congenital malformations. Non-singleton births and stillbirths were excluded from the study, which could potentially prevent detection of some risks. The inherent limitations of observational data are difficult to avoid at this stage of COVID-19 vaccination given that pregnant women were excluded from initial preauthorization trials. However, this large cohort study provides broad and compelling evidence supporting the safety of the BNT162b2 vaccine in pregnant women with respect to infant outcomes. Providers can thus be even more confident in recommending this vaccine to pregnant patients.

Click to read the study in JAMA Pediatrics

Relevant Reading: mRNA COVID-19 vaccines in pregnancy: A systematic review

In-Depth [retrospective cohort]: Data were obtained from a database including 26.7% of the Israeli population. 24,288 live births between March and September 2021 were included. Within the group unexposed to the vaccine, 2,241 infants were exposed to a maternal SARS-CoV-2 infection. Stabilized inverse probability of treatment weights (IPTWs) were used to balance the groups with respect to baseline maternal demographics, including maternal age, parity, and socioeconomic status. Rates of early preterm birth were significantly higher in the unexposed group with a risk ratio of 0.45 (95% confidence interval 0.29-0.70), though there was no significant difference in overall preterm birth. Analysis of risk of congenital anomaly was performed in a subgroup including only infants whose mothers were vaccinated in the first trimester, yielding a risk ratio of 0.69 (0.44-1.04) for vaccine exposure. In a sensitivity analysis excluding mothers who had SARS-CoV-2 infection during pregnancy, the only change in relative outcomes observed was a significantly increased risk of jaundice requiring phototherapy in vaccine-exposed infants (1.46; 1.06-2.06).

RELATED REPORTS

SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring

Molnupiravir and nirmatrelvir-ritonavir reduce COVID-19 mortality in hospitalized patients

Past infection with pre-omicron variants of COVID-19 protects against re-infection

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #Pfizer-BioNTechcovid vaccineCOVID-19pregnancy
Previous Post

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

Next Post

Cervical intraepithelial neoplasia grade 3 associated with adverse pregnancy outcomes

RelatedReports

Paternal factors associated with short interpregnancy interval
Infectious Disease

SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring

March 29, 2023
SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant
Infectious Disease

Molnupiravir and nirmatrelvir-ritonavir reduce COVID-19 mortality in hospitalized patients

March 29, 2023
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Past infection with pre-omicron variants of COVID-19 protects against re-infection

March 28, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 11

March 23, 2023
Next Post
5-FU a promising treatment for CIN-2

Cervical intraepithelial neoplasia grade 3 associated with adverse pregnancy outcomes

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19

Single-cycle adjuvant chemotherapy may be effective in stage I testicular cancer

Chemotherapy not associated with an increased COVID-19 mortality risk in active cancer patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options